- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Patent holdings for IPC class C07D 295/155
Total number of patents in this class: 383
10-year publication summary
|
43
|
24
|
27
|
29
|
19
|
15
|
28
|
15
|
18
|
12
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4848 |
10 |
| The Regents of the University of California | 20230 |
10 |
| Duke University | 3103 |
7 |
| Boehringer Ingelheim International GmbH | 4648 |
6 |
| Amyris, Inc. | 381 |
6 |
| The Cooper Health System | 40 |
6 |
| Nerviano Medical Sciences S.r.l. | 251 |
6 |
| Janssen Pharmaceutica N.V. | 3349 |
5 |
| Abbott Laboratories | 2365 |
5 |
| Aurimmed Pharma, Inc. | 7 |
5 |
| CHDI Foundation, Inc. | 106 |
5 |
| SRI International | 997 |
5 |
| Tetraphase Pharmaceuticals, Inc. | 51 |
5 |
| VALO Health, Inc. | 176 |
5 |
| Centre National de La Recherche Scientifique | 10635 |
4 |
| President and Fellows of Harvard College | 6024 |
4 |
| Abbvie Inc. | 1812 |
4 |
| Arena Pharmaceuticals, Inc. | 362 |
4 |
| Genfit | 281 |
4 |
| Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences | 75 |
4 |
| Other owners | 273 |